Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-GIO: Effect of esomeprazole on afatinib exposure in NSCLC
2017-001284-20Phase 4Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Area under the concentration-time curve (AUC) of afatinib. Started May 2017; status: active.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-001284-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001284-20.